ストックスクリーナーアプリを入手
9.56
1.16%
0.11
アフターアワーズ：
9.56
前日終値:
$9.45
開ける：
$9.35
24時間の取引高:
810.53K
Relative Volume:
2.41
時価総額：
$539.51M
収益：
-
当期純損益:
$-72.89M
株価収益率:
-3.918
EPS:
-2.44
ネットキャッシュフロー:
$-68.47M
1週間 パフォーマンス:
+0.42%
1か月 パフォーマンス:
-0.21%
6か月 パフォーマンス:
+8.27%
1年 パフォーマンス:
+58.02%
1日の値動き範囲:
$9.26
$9.81
1週間の範囲:
$9.17
$9.99
52週間の値動き範囲:
$5.9433
$16.90
Astria Therapeutics Inc Stock (ATXS) Company Profile
ATXS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
9.56 | 539.51M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-29 | 開始されました | TD Cowen | Buy |
| 2023-03-28 | 開始されました | Evercore ISI | Outperform |
Astria Therapeutics Inc (ATXS) 最新ニュース
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes $613,000 Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics expands stock incentive plan - Investing.com
Astria Therapeutics Expands Stock Incentive Plan - TipRanks
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.60 Consensus PT from Brokerages - MarketBeat
Is Astria Therapeutics (ATXS) Stock Outpacing Its Medical Peers This Year? - MSN
Short Interest in Astria Therapeutics, Inc. (NASDAQ:ATXS) Grows By 8.6% - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Charles Schwab Investment Management Inc. Has $3.46 Million Stock Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
ATXSAstria Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Astria’s OX40 antagonist gains US IND clearance for atopic dermatitis - BioWorld Online
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE - Business Wire
FDA clears Astria Therapeutics' new AD drug for trial By Investing.com - Investing.com Canada
Astria's Navenibart Shows Remarkable 95% HAE Attack Reduction in Phase 1b/2 Trial Results - StockTitan
Astria Therapeutics, Inc. Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis - Marketscreener.com
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis - Business Wire
Astria Therapeutics' Novel Atopic Dermatitis Drug STAR-0310 Gets FDA Green Light for Clinical Trials - StockTitan
(ATXS) Long Term Investment Analysis - Stock Traders Daily
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by Fmr LLC - Defense World
Fmr LLC Buys 1,767,714 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Intech Investment Management LLC Makes New $228,000 Investment in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Redmile Group LLC Takes $3.42 Million Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
RA Capital Management L.P. Has $56.21 Million Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Walleye Capital LLC Has $1.92 Million Stock Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Exciting Opportunities at Astria! New Moves Signal Growth! - Jomfruland.net
Vestal Point Capital LP Acquires 750,000 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Trend Tracker for (ATXS) - Stock Traders Daily
Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema - Seeking Alpha
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $25.60 - MarketBeat
Astria Therapeutics Reports Q3 2024 Financial Results - MSN
Equities Analysts Offer Predictions for ATXS FY2024 Earnings - MarketBeat
Astria Therapeutics’ (ATXS) Buy Rating Reiterated at HC Wainwright - Defense World
Astria Therapeutics (NASDAQ:ATXS) Price Target Raised to $28.00 - Defense World
Astria Therapeutics (NASDAQ:ATXS) Shares Down 5.3%What's Next? - MarketBeat
RA Capital Management, L.P. Expands Stake in Astria Therapeutics Inc - GuruFocus.com
Vestal Point Capital, LP Increases Stake in Astria Therapeutics Inc - GuruFocus.com
Oppenheimer Forecasts Strong Price Appreciation for Astria Therapeutics (NASDAQ:ATXS) Stock - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Shares Gap Up on Analyst Upgrade - MarketBeat
Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth - Simply Wall St
Astria's HAE Drug Shows 96% Attack Reduction; Phase 3 Set for Q1 2025 | ATXS Stock News - StockTitan
Astria Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference - sharewise
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - Yahoo Finance
FMR LLC Acquires Significant Stake in Astria Therapeutics Inc - GuruFocus.com
Astria Therapeutics (NASDAQ:ATXS) Stock Crosses Above 50-Day Moving AverageHere's Why - MarketBeat
How to Take Advantage of moves in (ATXS) - Stock Traders Daily
Vanguard Group Inc's Strategic Acquisition in Astria Therapeutics Inc - GuruFocus.com
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - XM
Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting - Business Wire
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Buy" from Analysts - MarketBeat
Objective long/short (ATXS) Report - Stock Traders Daily
Astria Therapeutics Inc (ATXS) 財務データ
収益
当期純利益
現金流量
EPS
Astria Therapeutics Inc (ATXS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Morabito Christopher | Chief Medical Officer |
Apr 01 '24 |
Sale |
13.59 |
10,000 |
135,939 |
0 |
| PERCEPTIVE ADVISORS LLC | Director |
Feb 01 '24 |
Buy |
12.09 |
2,481,350 |
29,999,522 |
4,873,721 |
| Morabito Christopher | Chief Medical Officer |
Jan 29 '24 |
Option Exercise |
3.87 |
9,200 |
35,604 |
9,200 |
| Morabito Christopher | Chief Medical Officer |
Jan 26 '24 |
Option Exercise |
3.87 |
800 |
3,096 |
800 |
| Morabito Christopher | Chief Medical Officer |
Jan 29 '24 |
Sale |
11.15 |
9,200 |
102,552 |
0 |
| Morabito Christopher | Chief Medical Officer |
Jan 26 '24 |
Sale |
11.02 |
800 |
8,812 |
0 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):